22 results about "Glucose deprivation" patented technology

The invention belongs to the field of biosensing and fluorescence imaging, and particularly relates to a fluorescent probe compound and application thereof. The probe compound is a compound as shown in a formula I or a compound as shown in a formula II, or a pharmaceutically acceptable salt thereof; the structures of the compound in the formula I and the compound in the formula II are shown in the specification, and the definition of each group is shown in any embodiment of the invention. The fluorescent probe compound shows rapid and high reactivity to oxidizing free radicals, the generated fluorescent compound is high in fluorescence intensity and good in stability, and early diagnosis can be carried out on ferroptosis-related disease models such as oxygen-glucose deprivation / reperfusion and drug liver injury on living cell or living body levels and the like. I II

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

This invention discloses a micropeptide, its encoding nucleic acid, and its application in regulating inflammatory activation of microglia. The amino acid sequence of the micropeptide is shown in SEQ ID NO:3. Simultaneously, this invention discloses the nucleic acid encoding the micropeptide, which contains either the nucleotide sequence shown in SEQ ID NO:1 or the nucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is a small open reading frame located within the sequence of SEQ ID NO:1. This invention validated the translational expression of the micropeptide in microglia by constructing an EGFP reporter gene fusion vector and a SUMO tag fusion expression vector. Functional experiments showed that under oxygen-glucose deprivation / reperfusion injury conditions, the micropeptide significantly inhibited inflammatory activation of microglia. This invention provides a new potential target and candidate drug for the treatment of neuroinflammatory diseases such as stroke.

The invention relates to the technical field of biological medicine and polymer targeted delivery, and provides an oligodendrocyte-derived exosome and application thereof in preparation of a medicine for treating traumatic brain injury. Comprising the following steps: separating and culturing primary oligodendroglia cells from brain tissues; placing the maturely cultured oligodendroglia cells in a sugar-free and serum-free culture medium, performing oxygen-glucose deprivation treatment in an anoxic environment, then continuously culturing in a normal sugar-containing culture medium under a normal oxygen condition, and collecting cell culture supernate; and separating the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment from the supernate by adopting a gradient ultracentrifugation method to obtain the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment. The exosome derived from the oligodendroglia is applied to preparation of the medicine for treating the traumatic brain injury and has the advantages of being high in targeting performance and good in penetrability, that is, the exosome is used as a natural carrier, the defect that a traditional traumatic brain injury medicine is difficult to penetrate through a blood brain barrier is perfectly overcome, and the exosome can efficiently enter brain tissue and be taken by microglia.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

This invention discloses a myocardial protective composition of *Dioscorea opposita* polysaccharide, its preparation method, and its application, belonging to the field of natural products and functional foods. The active ingredient of the composition is one or a combination of *Dioscorea opposita* polysaccharide and *Dioscorea cirrhosa* polysaccharide. This polysaccharide is a neutral heteropolysaccharide mainly composed of glucose, with glucose accounting for more than 96% of the total monosaccharide mass. The two polysaccharides have highly similar molecular weight distributions and core structural characteristics. This invention demonstrates that the yam polysaccharide can dose-dependently improve the viability of cardiomyocytes after oxygen-glucose deprivation / reoxygenation injury, and reduce the levels of myocardial injury markers CK-MB and cTnT, and the oxidative stress marker 8-OHdG. Its core mechanism of action is the regulation of the MyD88-mediated MAPK / NF-κB signaling pathway, inhibiting the stress and inflammatory cascade response of cardiomyocytes. The yam polysaccharide composition of this invention has widely available raw materials, a simple preparation process, and high safety. It can be widely used in the preparation of pharmaceuticals, health foods, functional foods, and other products for the prevention / improvement of myocardial ischemia-reperfusion injury, and has broad application prospects.

The application discloses functions and uses of a kind of pentacyclic triterpenoid compounds in preventing and / or treating neurodegenerative diseases, and the compounds are obtained by isolating and extracting from Cynomorium songaricum Rupr medicinal materials.The inventors found that the compounds have significant protective effects on glutamic acid-induced nerve cell injury and oxygen-glucose deprivation-induced nerve cell injury during pharmacological activity evaluation of the compounds, and thus can be used for treating and preventing neurodegenerative diseases such as stroke, brain injury, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Alzheimer's disease, and can be developed into drugs.

The invention discloses application of a cotton flower extract in preparation of a medicine for preventing and treating myocardial infarction, and relates to the technical field of biological medicines. Systematic cell experiments and animal experiments prove that the cotton flower extract has remarkable technical effects in prevention and treatment of myocardial infarction related diseases. In the cellular level, the extract can reverse H2O2-induced myocardial cell injury in a dose-dependent manner; the compound has a remarkable inhibiting effect on ISO-induced myocardial fibroblast abnormal activation and proliferation, meanwhile, the survival rate of myocardial cells in an oxygen-glucose deprivation model can be increased, and it is proved through a scratch experiment that the compound can effectively inhibit myocardial fibroblast migration. In animal experiments, the extract can significantly improve the cardiac function and can effectively reverse myocardial injury caused by myocardial infarction. The invention clarifies the new application value of the cotton flower extract, and provides a novel medicine for preventing and treating myocardial infarction, myocardial injury, myocardial fibrosis and heart failure.

The invention belongs to the field of biotechnology and medicine, provides application of thioredoxin TXN1 and TRP14 as a bidirectional switch for regulating and controlling a cell death mode and application of an anti-cancer drug, and particularly relates to new application of TXN1 and TRP14. The invention reveals that TXN1 and TRP14 play a role of a bidirectional regulation switch in regulating the sensitivity of non-small cell lung cancer cells to different programmed death modes (including apoptosis, ferroptosis and disulfide death) for the first time. By reducing the activity or expression of TXN1 or TRP14, the sensitivity of cancer cells to apoptosis inducers and ferroptosis inducers can be enhanced, but the resistance of the cancer cells to glucose deprivation-induced disulfide death is remarkably enhanced. The discovery shows that inhibition of TXN1 / TRP14 can be combined with an apoptosis / ferroptosis inducer to treat cancers; meanwhile, an inhibitor aiming at TXN1 / TRP14 can be used for preventing or treating diseases related to disulfide death. The invention provides a cancer treatment composition based on the discovery, a drug screening method and biomarker application.

The invention belongs to the technical field of medicines, and discloses application of a magnolol nitrone derivative HL-3 in preparation of medicines for preventing or treating cerebral infarction. The HL-3 shows a remarkable treatment effect in both in-vitro and in-vivo experiments. In an in-vitro experiment, the HL-3 can effectively relieve damage caused by oxygen glucose deprivation / reoxygenation (OGDR) of SK-N-SH cells under the concentration of 10 micromoles (mu M), the cell survival rate is remarkably increased, and it is indicated that the HL-3 has a high neuroprotective effect. In an integral animal experiment, the HL-3 shows an obvious treatment effect on transient middle cerebral artery occlusion (tMCAO) and permanent middle cerebral artery occlusion (pMCAO) models of SD (Sprague Dawley) rats under the dosage of 1mg / kg and 10mg / kg. Specifically, the cerebral infarction volume is reduced, and the neurological function score is improved. The results show that the HL-3 is effective in various models, has wide applicability and remarkable treatment potential, and provides a new and effective drug choice for cerebral infarction treatment.

The invention discloses steroid saponin compounds in longstalk allium macrostemon, a preparation method of the steroid saponin compounds and application of the steroid saponin compounds in preparation of medicines for improving and / or treating myocardial infarction. According to the invention, two compounds, i.e., long-stalk allium macrostemon saponin A and degalactotigonin, are separated from long-stalk allium macrostemon. In an MI mouse model, the two compounds can significantly improve heart function indexes (EF and FS), reduce myocardial infarction area, inhibit inflammatory infiltration and collagen deposition, and improve pathological injury; the levels of cTnI, LDH and CK-MB are reduced; the expression of inflammation related factors and proteins (caspase-1, ASC, GSDMD, IL-1beta and IL-18) can be inhibited. In-vitro experiments prove that the two compounds can effectively protect H9c2 myocardial cells damaged by oxygen-glucose deprivation. The two compounds can be used for preparing medicines for improving and / or treating myocardial infarction, and can be used for manufacturing chemical raw material medicines and preparations.

The application discloses functions and uses of a kind of pentacyclic triterpenoid compounds in preventing and / or treating neurodegenerative diseases, and the compounds are obtained by isolating and extracting from Cynomorium songaricum Rupr medicinal materials.The inventors found that the compounds have significant protective effects on glutamic acid-induced nerve cell injury and oxygen-glucose deprivation-induced nerve cell injury during pharmacological activity evaluation of the compounds, and thus can be used for treating and preventing neurodegenerative diseases such as stroke, brain injury, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Alzheimer's disease, and can be developed into drugs.

This invention belongs to the field of biosensing and fluorescence imaging, specifically relating to a fluorescent probe compound and its applications. The probe compound is a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof; the structures of compounds of formula I and formula II are shown below, and the definitions of each group are as described in any embodiment herein. The fluorescent probe compound of this invention exhibits rapid and high reactivity to oxidative free radicals, and the generated fluorescent compound has high fluorescence intensity and good stability. It can be used for early diagnosis of ferroptosis-related disease models, such as oxygen-glucose deprivation / reperfusion and drug-induced liver injury, at the cellular or in vivo level. I II

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for preventing or treating ischemic encephalopathy and application thereof, and the pharmaceutical composition comprises ginsenoside Rg1, ruscogenin and schizandrin. In an in-vitro oxygen-sugar deficiency / reperfusion induced bEnd.3 cell injury model, compared with a corresponding monomer component, the pharmaceutical composition disclosed by the invention can obviously recover the cell activity. In an in-vivo rat middle cerebral artery obstruction reperfusion model, the pharmaceutical composition disclosed by the invention can be used for remarkably reducing the cerebral infarction volume, improving the neural behavior function and recovering cerebral blood flow in an ischemic area. Meanwhile, toxicity is not shown in the continuous administration period. The results show that the pharmaceutical composition has an application prospect in treatment of cerebral arterial thrombosis, especially in improvement of ischemia reperfusion prognosis by restoring blood flow.

The utility model relates to the field of in-vitro simulation oxygen-glucose deprivation re-reoxygenation experiments, and discloses an in-vitro simulation oxygen-glucose deprivation re-reoxygenation device which comprises a sealing box, a plurality of sets of pore plate placing frames are arranged on the inner wall of the sealing box, and an air inlet pipe and an air outlet pipe are arranged on the two opposite side faces of the sealing box respectively. The end part, far away from the sealing box, of the air outlet pipe is connected with an oxygen detector; the end part, far away from the sealing box, of the gas inlet pipe is connected with a mixed gas supply source; a needle valve is arranged on the air outlet pipe, and an adjusting valve is arranged on the air inlet pipe. According to the in-vitro oxygen-glucose deprivation simulation and reoxygenation device provided by the utility model, the sealed box, the gas inlet pipe, the gas outlet pipe, the oxygen detector and the mixed gas supply source are simple models which are built by simple instruments commonly existing in the existing experiment; the device can be widely applied to simulation of the hypoxia state of intravascular cell culture in experiments, and the experiment cost of in-vitro simulation of oxygen-glucose deprivation and reoxygenation is greatly reduced.

The invention discloses a small molecule activator targeting nerve cell aromatase and application of the small molecule activator in cerebral ischemia injury, and belongs to the technical field of biological medicine. The activator can directly enhance the catalytic activity of aromatase without significantly affecting the gene transcription of aromatase, so that the local estrogen level in the brain is accurately improved, and the neuroprotection effect is achieved. The neuron aromatase is specifically activated, so that the side effect of systemic estrogen treatment is avoided. In-vivo and in-vitro experiments prove that the concentration of estrogen in a target region can be effectively improved through local intracerebral administration, and the survival rate of neurons in an oxygen-glucose deprivation / reoxygenation injury model is remarkably improved. The pharmaceutical composition provided by the invention is suitable for local administration or systemic administration of a central nervous system, can be combined with the existing therapy, and provides a brand new treatment strategy and drug candidate for cerebral ischemia injury.

The invention belongs to the technical field of biological medicines, and particularly relates to treatment application of a targeted exosome in improving blood-brain barrier destruction of acute ischemic stroke, and the targeted exosome is an exosome from brain microvascular endothelial cells subjected to oxygen-glucose deprivation treatment, and is an exosome carrying CD151-siRNA (siCD151). According to the technical scheme, the screened CD151 is a key molecule for regulating and controlling the immune homeostasis of the endothelial cells. Meanwhile, the exosome from brain microvascular endothelial cells subjected to oxygen-glucose deprivation treatment is obtained to serve as a delivery carrier, and siCD151 is carried to construct an Exo-siCD151 system. The system can maintain the immune homeostasis of the endothelial cells by reducing the CD151 level of the ischemic-damaged endothelial cells in a targeted manner, so that the aims of repairing the blood-brain barrier and improving the cerebral ischemia prognosis are fulfilled.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

The invention relates to an anti-cancer drug for synergistically regulating and controlling pyroptosis of pancreatic cancer cells based on magnolol and glucose metabolism and application of the anti-cancer drug. The anti-cancer drug is a key enzyme GLUT1 inhibitor for magnolol and glucose metabolism. By combining magnolol with a glucose deprivation / GLUT1 inhibitor (such as BAY-876) and by inhibiting mitochondrial autophagy (PINK1 degradation) and mitochondrial ROS accumulation and triggering a new mechanism of apoptosis-pyroptosis conversion, the limitation that a traditional natural product only depends on an apoptosis pathway is broken through; the immunoregulation of mitochondrial autophagy inhibition and pyroptosis induction is creatively associated; metabolic intervention induced pyroptosis is directly associated with pancreatic cancer'immune cold 'microenvironment remodeling, and an important theoretical basis is provided for natural product combined immunotherapy. Meanwhile, a CDX model (magnolol combined with a GLUT1 inhibitor) and ketogenic diet simulation metabolism intervention are combined, and a closed-loop verification system from a molecular mechanism to in-vivo treatment is established, so that clinical development of metabolism intervention-natural product-immune combined treatment can be promoted.

The application discloses application of 2,3-dihydroxyacetophenone in treating ischemic diseases, the compound has pharmacological effects of resisting brain damage of mice caused by cerebral ischemia, and has pharmacological activities of resisting neuron damage caused by oxygen-glucose deprivation, and is expected to be developed into a drug for treating ischemic diseases.

This invention discloses a Hotan summer apple beverage, its preparation method, and its application, belonging to the field of pharmaceutical technology. The Hotan summer apple beverage of this invention comprises the following components, by weight: 500-1000 parts Hotan summer apple extract, 100-200 parts Hotan red grape extract, 1-2 parts Hotan rose, 0.1-0.5 parts saffron, and 20-60 parts flavoring agent. This Hotan summer apple beverage of this invention can significantly increase the proliferation level of H9C2 cells damaged by oxygen-glucose deprivation, and significantly decrease the expression of the serum myocardial injury marker lactate dehydrogenase (LDH), indicating that the beverage of this invention has a protective effect on cardiomyocytes. Compared with the commonly used inhibitor Acetylcysteine, this Hotan summer apple beverage of this invention is made from ingredients that are both food and medicine, with no side effects from long-term use, making it more suitable for long-term use by patients with chronic diseases. The materials in this beverage are Hotan summer apple, Hotan red grape, Hotan rose, and saffron, which are products of large-scale cultivation, with high yield and low cost. The preparation process is simple, reducing the cost of medication.